Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01118078
Other study ID # AREN10B2
Secondary ID NCI-2011-02230CD
Status Completed
Phase N/A
First received May 5, 2010
Last updated May 17, 2016
Start date May 2010

Study information

Verified date May 2016
Source Children's Oncology Group
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

This research study is studying biomarkers in tissue samples from patients with high-risk Wilms tumor. Studying samples of tissue from patients with cancer in the laboratory may help doctors to learn more about changes that occur in DNA and identify biomarkers related to cancer.


Description:

OBJECTIVES:

I. To assess genomic gains and losses in high risk renal tumors, including up to 80 favorable histology Wilms tumors that relapse (RFHWT), 50 anaplastic Wilms tumors (UHWT), 15 clear cell sarcomas of the kidney (CCSK), and 40 rhabdoid tumors (RT) using a high density genetic platform to survey for recurrent copy number variations and allelic imbalances. II. To define transcription patterns within 80 RFHWT, 50 UHWT, 15 CCSK, and 40 RT using a high throughput platform for global gene expression. III. To define DNA methylation patterns within 80 RFHWT, 50 UHWT, 15 CCSK, and 40 RT using a high throughput platform. IV. To identify genetic mutations involved in the pathogenesis of Wilms tumor, and in the development of relapse and anaplasia through the study of 80 RFHWT, 50 UHWT, 15 CCSK, and 40 RT using next generation sequencing tools.

V. To facilitate the integration of the above databases and allow meaningful access by investigators through the infrastructure provided by TARGET, including its data portal and associated caBIG tool.

OUTLINE: This is a multicenter study.

Archived tumor tissue samples are analyzed for DNA copy number determination, gene expression, DNA methylation, and genomic re-sequencing by array-based methods, including PCR analysis, methylation-specific reverse transcriptase-PCR (RT-PCR), and quantitative RT-PCR.


Recruitment information / eligibility

Status Completed
Enrollment 185
Est. completion date
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender Both
Age group N/A to 16 Years
Eligibility Inclusion Criteria:

- Diagnosis of high-risk Wilms tumor meeting = 1 of the following criteria:

- Relapsed disease

- Anaplastic disease

- Clear cell sarcomas of the kidney

- Rhabdoid tumors

- Registered on NWTS-4, NWTS-5 (now COG-Q9401), or participation in AREN03B2 protocols with clinical follow-up > 3 years

- Banked frozen tumor samples and paired normal DNA available with clinical data points, including the following:

- Age, race, and gender

- Stage and reason for stage

- Tumor weight

- Associated precursor lesions (rests)

- Histologic subtype

- Site and time of recurrence

- Days of follow-up

- Time and reasons for death (e.g., tumor, toxicity, infection, or other)

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Intervention

Genetic:
DNA methylation analysis
Undergo DNA methylation analysis
gene expression analysis
Undergo gene expression analysis
microarray analysis
Undergo microarray analysis
reverse transcriptase-polymerase chain reaction
Undergo RT-PCR
Other:
diagnostic laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States Children's Oncology Group Monrovia California

Sponsors (2)

Lead Sponsor Collaborator
Children's Oncology Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Genomic gains and losses in high-risk Wilms tumor After completion of biomarker analysis No
Primary Transcription patterns involved in the pathogenesis of Wilms tumor After completion of biomarker analysis No
Primary Genetic mutations involved in the pathogenesis of Wilms tumor After completion of biomarker analysis No
See also
  Status Clinical Trial Phase
Completed NCT01305200 - Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Phase 3
Completed NCT00101270 - Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Phase 1
Completed NCT01614808 - Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor N/A
Completed NCT01502410 - Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Phase 2
Completed NCT00831844 - Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Phase 2
Active, not recruiting NCT00638898 - Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor Phase 1
Completed NCT01586104 - Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases N/A
Completed NCT00897637 - Gene Expression Profiles to Categorize Wilms Tumors N/A
Completed NCT00309907 - Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Phase 2
Completed NCT00331643 - Ixabepilone in Treating Young Patients With Refractory Solid Tumors Phase 2
Completed NCT00012181 - Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas Phase 1